Pharmaceuticals, Biotechnology and Life Sciences
Erytech Pharma, the French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, has purchased ordinary shares of the company in a private placement reserved for a specified category of investors (the “Reserved Offering”).
Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, has appointed Neil Clark as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately.
BioMarin Pharmaceutical and Par Pharmaceutical have entered into a settlement agreement that resolves patent litigation in the United States (U.S.) related to BioMarin’s Kuvan 100mg oral tablets and powder for oral solution in 100mg packets.
Innovative UK poured almost a million pounds to a developer of cell therapies including hematopoietic cell replacement therapies, Plasticell.
Diplomat Pharmacy and Corizon Health have entered into three-year agreement according to which Diplomat will provide pharmacy services and dispense limited-distribution specialty drugs for Corizon Health’s clients and support its in-house mail-order pharmacy, PharmaCorr
NIH-funded preclinical studies suggest designer drug may treat ALS and spinocerebellar ataxia 2.
Respira Therapeutics, a privately held pharmaceutical company developing innovative inhaled therapies to treat pulmonary hypertension and other pulmonary diseases, has entered into a strategic collaboration with United Therapeutics Corporation for the development and exclusive license of Respira’s inhaled drug-device product, RT234, for pulmonary hypertension indications in North America.
Roche has announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis.
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Active Biotech for its investigational novel agent tasquinimod, for the treatment of multiple myeloma.
argenx has initiated a Phase II trial of ARGX-110 as a monotherapy in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL).